<DOC>
	<DOCNO>NCT00069901</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy CT-2103 ( poly ( L ) glutamate-paclitaxel ) combination carboplatin treatment patient Stage III IV ovarian primary peritoneal cancer .</brief_summary>
	<brief_title>Phase II CT-2103/Carboplatin Ovarian Cancer</brief_title>
	<detailed_description>CT-2103 pharmaceutical link paclitaxel , active ingredient Taxol ( R ) , biodegradable polyglutamate polymer . The objective trial evaluate toxicity , estimate response rate , progression-free survival overall survival patient newly diagnose stage III IV ovarian primary peritoneal carcinoma treat CT-2103 combination carboplatin .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion criterion : Histologicallyconfirmed stage III IV ovarian carcinoma primary peritoneal cancer patient appropriate debulking surgery ovarian peritoneal carcinoma . Patients must recover initial surgery must enter study later 12 week surgery . ECOG performance score 0 , 1 , 2. absolute neutrophil count ( ANC ) least 1,500/µL . platelet least 100,000/µL . hemoglobin least 10 g/dL . creatinine great 1.5 time upper limit normal ( ULN ) . bilirubin great 1.5 x ULN ( liver metastasis present , SGOT SGPT great 2.5 x ULN , liver metastasis present , SGOT SGPT may great 5 x ULN . Alkaline phosphatase great 2.5 x ULN . Exclusion : Current diagnosis epithelial ovarian tumor low malignant potential ( borderline carcinoma ) Germ cell tumor , sex cordstromal tumor , carcinosarcoma , mixed mullerian tumor carcinosarcomas , metastatic carcinoma site ovary , low malignant potential tumor include call micropapillary serous carcinoma . Synchronous primary endometrial cancer history primary endometrial cancer . Evidence invasive malignancy present within 3 year study , exception nonmelanoma skin cancer specific malignancy note . Any prior treatment , initial debulking surgery , cancer treat study . Patients may receive prior adjuvant chemotherapy localize breast cancer , therapy complete least 3 year registration study patient remain free recurrent metastatic disease . Prior radiotherapy portion abdominal cavity pelvis . Prior radiation localize cancer breast , head neck , skin permit , complete least 3 year registration study patient remain free recurrent metastatic disease . Administration investigational drug within 26 week first treatment study . Toxic manifestation previous treatment ( except alopecia ) must stable 4 week . Presence active hepatitis , either acute chronic . Presence active infection require antibiotic antiviral therapy . Pregnant woman nurse mother .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
</DOC>